Peter Yorke

Voyomotive is a connected-vehicle technology company delivering a comprehensive platform for consumer and commercial telematics, diagnostics, and vehicle data applications. The Voyomotive platform combines intelligent software and cloud-based services to enable advanced telematics and diagnostics across a wide range of use cases. At its core, the platform provides secure, scalable access to vehicle data, and empowers channel partners and third-party developers to build high-value products for auto service providers, fleets, parts distributors, insurers, and consumers. VOYOLink is Voyomotive’s integration layer for the automotive service ecosystem, including support for Right to Repair–driven data access. It enables secure, consent-based connections between vehicles and service provider IT systems, allowing diagnostic and telematics data to integrate into existing shop, fleet, and partner workflows. VOYOTRAK is Voyomotive’s fleet management solution for both commercial fleets and consumer multi-vehicle use cases, delivering tracking, alerts, and operational insights. VOYOTRAK is designed to scale from basic vehicle monitoring to more advanced fleet visibility and management. Together, the Voyomotive platform, VOYOLink, and VOYOTRAK provide flexible, modular solutions that support deployments ranging from consumer applications to enterprise and commercial vehicle operations.

EndoVention is a San Francisco based company developing catheter systems to perform thrombectomy procedures and to provide embolic protection. Based upon the company’s proprietary intellectual property and designs, the EndoVention catheter systems are designed to treat a number vascular ailments including Deep Vein Thrombosis, Acute Lower Extremity Ischemia, and Stroke. To date, EndoVention is the recipient of two DOD sponsored development grants, over $2 million in capital, and has developed advanced prototypes of its first product the Expandable Mouth Catheter which were successfully tested in animal models.

Co-founder and Board Member. Sherpa Interventional Systems developed a proprietary line of endovascular products used in interventional radiology/cardiology laboratories and the operating room. As co-founder/CFO, attained private equity and SBA debt financing, FDA regulatory clearance, and assumed all financial/operating activities of the LLC. Established key corporate relationships for prototyping, manufacturing and order fulfillment outsourcing. Working with the CEO, developed a national network of independent distributors as well as direct sales relationships. Based solely on Sherpa’s direct sales efforts, the company established accounts with over 100 US medical centers. Company was issued several multinational patents including in the USA, Europe and Japan. Sherpa was started in early 2000 and joined company full time when the first product was released in Q2, 2001. The company was acquired by the Stryker Corporation in April 2004.

@tlas e-Solutions, Inc developed an XML based server technology to automate the integration of data between email messages, Microsoft desktop software and high end business applications. The @tlas technology provided a new form of application interface that can concurrently support multiple programs and file formats (e.g. ERP, CRM, SFA, etc.) and seamlessly post user input to target applications. In addition the Company had a consulting practice with over 14 employees focusing on ERP implementation, Project Management, and systems integration. As CFO, responsibilities included serving on the Board of Directors, set up and administration of financial systems/activities, playing lead role in fund raising/business development activities.

AMP&A manage venture capital funds and provides strategic consultancy services to companies in the lifescience sector. Responsibilities as CIO entailed senior level leadership in all activities related to venture capital investment, fund raising, and a supporting role in transaction advisory services. Served as senior investment manager and member of AMP&A’s Investment Committee for two AMP&A associated venture capital funds - TechAMP International and GeneChem. Took lead role in generating deal flow, conducting due diligence, term sheet negotiations and closing financial rounds. Responsible for overseeing and managing the investment activities of direct investment team comprised of 6 professionals. Had senior role in TechAMP fund raising activities including drafting of PPM, road show presentations, investor negotiations and other syndication activities.

Affiliated with Montgomery Securities, Montgomery Medical Ventures was a venture capital partnership investing in domestic and international health care companies. Projects include those in the pharmaceutical, biotechnology, medical device, and health care service sectors. Investment experience includes taking both lead and supporting roles in venture financings (early, mid and late stage), mergers and acquisitions, financial restructurings, and project finance. Portfolio responsibilities entailed sourcing deal flow, conducting all elements of due diligence for initial and follow on financings, investment syndication, term sheet negotiation, developing corporate joint venture partnerships. Strong experience working with senior management teams to develop strategic operating plans, budgets and board packages. Active participants in the following deals: IMED (medical equipment company acquired for $105 million), HCI Scotland ($325 million UK project finance), and multiple venture placements in the $1 million to $5 million range. Board of Directors: Redwood MicroSystems, Ossificon Additional portfolio responsibilities included Advanced Medical Technologies, Control Therapeutics, Himedics Corp., Gliatech Inc., Verax Corp.

Medical venture fund investing early, mid, late stage companies in addition to mergers and acquisitions. Conducted scientific, marketing and financial due diligence on proposed investments.

HCI developed a medical center and referral network to provide advanced tertiary care to patients from Europe and the Middle East. Seconded from MMV as part of HCI’s founding management team, the company grew from six managers to over 400 employees in 30 months with operations and partnerships in over 8 countries. In addition to working with the management team to raise initial capital ($325 million of equity and debt financing), operating responsibilities included both establishing and managing offices in strategic markets including those in the Mediterranean, Middle Eastern and Central European regions. Focus of these operations was to establish a network of referring physicians, develop strategic relationships with academic and government health care institutions, promote awareness to potential patients and manage the process of patient referrals and payments of local insurers. Also working with HCI’s Co-Chairmen, conducted feasibility studies, developed proposals, and raised capital from international sources for the development of affiliated medical centers in Greece, Egypt, Czech Republic, and Saudi Arabia.

Burr, Egan, Deleage was a venture capital partnership with over $500 million under management. Responsibilities included sourcing new deal flow for early and late stage equity investments related to biotechnology and medtech. Conducted scientific, marketing and financial due diligence on proposed investments. Held position as an Associate while attending UCLA MBA program.